Tianying Wu | Oncology and Precision Medicine | Innovative Research Award

Published on by Oncology

“`html

Innovative Research Award

Tianying Wu
San Diego State University, United States

Tianying Wu
Affiliation San Diego State University
Country United States
Scopus ID 56174751700
Documents 51
Citations 1843
h-index 21
Subject Area Oncology and Precision Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-1679-3511

The Tianying Wu recognizes scholarly excellence demonstrated through impactful scientific investigations, sustained publication activity, and meaningful contributions to oncology and precision medicine. Tianying Wu of San Diego State University has established an academic profile characterized by interdisciplinary collaboration, high-quality publications, and measurable research influence within cancer-related biomedical sciences. The available scholarly indicators, including publication output, citation performance, and h-index, reflect consistent engagement in internationally recognized research activities.[1] [2]

Abstract

Tianying Wu’s academic profile reflects a productive research career in oncology and precision medicine supported by peer-reviewed publications and significant scholarly citations. The integration of laboratory research, translational science, and interdisciplinary collaboration contributes to advancing understanding of cancer biology and therapeutic strategies. Bibliometric indicators demonstrate sustained scientific visibility and academic engagement across international research communities.[1] [3]

Keywords

Oncology, Precision Medicine, Cancer Biology, Translational Research, Molecular Oncology, Biomarkers, Personalized Medicine, Clinical Research, Biomedical Science, Cancer Therapeutics.

Introduction

Modern oncology research increasingly emphasizes precision medicine approaches that integrate genomic discoveries with individualized patient care. Researchers working in this field contribute to improving diagnostic accuracy, therapeutic selection, and long-term clinical outcomes. Academic achievements are commonly evaluated using publication quality, citation metrics, collaborative research, and contributions to scientific innovation. Tianying Wu’s scholarly profile aligns with these internationally recognized indicators of academic excellence.[2] [4]

Research Profile

Affiliated with San Diego State University, Tianying Wu has developed an academic portfolio spanning oncology and precision medicine. The available Scopus metrics indicate 51 indexed publications, 1,843 citations, and an h-index of 21, reflecting sustained scholarly influence and consistent scientific productivity. Such metrics are widely used for assessing research visibility and long-term academic impact across biomedical disciplines.[1]

Research Contributions

Research contributions associated with this academic profile include participation in studies related to cancer biology, molecular mechanisms, translational medicine, and precision oncology. Such investigations support improved understanding of disease progression and therapeutic response while encouraging evidence-based clinical applications. Collaborative scientific research remains fundamental for accelerating innovation within modern oncology.[3] [5]

Publications

The publication record demonstrates sustained engagement with peer-reviewed scientific literature. Indexed articles contribute to ongoing discussions in oncology, biomedical research, and precision medicine while supporting future investigations through reproducible scientific methodologies. Citation performance further indicates continued academic relevance within the international research community.[1]

Research Impact

Research impact extends beyond publication counts by influencing scientific dialogue, interdisciplinary collaboration, and evidence-based healthcare. Citation metrics, h-index values, and continued referencing by other investigators collectively indicate scholarly visibility. These indicators provide objective evidence supporting recognition within competitive academic award programs.[2] [4]

Award Suitability

Based on publicly available academic indicators, Tianying Wu demonstrates qualifications consistent with consideration for the Innovative Research Award presented through the International Research Awards on Oncology and Cancer Research. Evaluation criteria including publication productivity, scholarly citations, research quality, interdisciplinary engagement, and measurable academic influence collectively support recognition within an international academic framework.[1] [5]

Conclusion

The scholarly profile of Tianying Wu reflects sustained academic productivity, meaningful citation performance, and ongoing engagement with oncology and precision medicine research. These measurable indicators represent important components of scientific excellence and support recognition through academic award initiatives dedicated to advancing cancer research and international scholarly collaboration.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Tianying Wu, Author ID 56174751700. Scopus.https://www.scopus.com/pages/authors/56174751700
  2. ORCID. (n.d.). Researcher Profile: Tianying Wu.https://orcid.org/0000-0003-1679-3511
  3. Crossref. (n.d.). Digital Object Identifier Handbook.https://doi.org/10.1038/nature
  4. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment.https://www.cancer.gov/research/areas/treatment/precision-medicine
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Award Information.https://oncology.pencis.com/

“`

Dr. Osnat Elyashiv | Oncology Therapy | Research Excellence Award

Published on by Oncology

Dr. Osnat Elyashiv | Oncology Therapy | Research Excellence Award 

Gynecologic Oncology Consultant | The Edith Wolfson University Medical Center | Israel

Dr. Osnat Oxana Elyashiv’s research centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers, integrating clinical trials, surgical outcomes, and translational science. Her work explores prognostic biomarkers such as platelet ratios and homologous recombination deficiency to guide personalized therapy. She has contributed to major international trials on targeted treatments like PARP inhibitors. Her studies also evaluate surgical strategies, emphasizing complete tumor resection as a key survival determinant. Additionally, she investigates cancer stem cell heterogeneity and metastasis patterns. Her research extends to imaging, lymph node assessment, and minimally invasive techniques. Overall, her work advances precision medicine, improving prognosis, treatment optimization, and patient-centered care in gynecologic cancers.

Citation Metrics (Google Scholar)

298
200
100
50
0

Citations

298

h-index

9

i10-index

9

Citations

h-index

i10-index

View Google Scholar Profile

Featured Publications

 

Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Permal Deo | Prostate Cancer | Best Researcher Award

Published on by Oncology

Dr. Permal Deo | Prostate Cancer | Best Researcher Award

Senior Lecturer | Clinical and Health Sciences, University of South Australia | Australia

Dr. Permal Deo is a distinguished food scientist and academic leader renowned for his contributions to nutrition, food biochemistry, and public health research. He holds a PhD in Food Biochemistry from Queen’s University Belfast, UK, where his doctoral work investigated the effects of food-derived advanced glycation end-products (AGEs) on oxidative stress and receptor activity in human cell lines. Complementing this, he earned a Master of Applied Science and Postgraduate Diploma from The University of Queensland, Australia, and a Bachelor of Science from The University of the South Pacific, Fiji. With over two decades of academic, research, and industry experience, Dr. Deo’s expertise encompasses food microbiology, food processing, functional foods, and the molecular pathways linking type 2 diabetes and Alzheimer’s disease. His research emphasizes the bioactivity of natural plant compounds and nutraceuticals in combating oxidative stress and inflammation, as well as the antimicrobial and food safety applications of electrochemically activated solutions. An accomplished mentor and research leader, he has supervised numerous postgraduate students and attracted more than AUD 2.5 million in competitive funding from prestigious bodies including the Australian Research Council, Diabetes Australia, and Horticulture Innovation. His extensive collaborations with institutions such as CSIRO, Monash University, and the University of Adelaide have advanced understanding in genome stability, indigenous food systems, and sustainable nutrition technologies. Widely recognized for his scholarly impact and leadership, Dr. Deo has presented at global scientific conferences and published influential studies in leading journals. His enduring scientific legacy is reflected through 944 citations, 57 documents, and an h-index of 19, underscoring his influential role in advancing the frontiers of food biochemistry, nutritional science, and biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Snelson, M., Tan, S. M., Clarke, R. E., De Pasquale, C., Thallas-Bonke, V., Deo, P., … & Coughlan, M. T. (2021). Processed foods drive intestinal barrier permeability and microvascular diseases. Science Advances, 7(14), eabe4841. Cited by: 148

2. Sim, D. P., Khazandi, M., Chan, W. Y., Deo, P., & Trott, D. J. (2019). Antimicrobial activity of thyme oil, oregano oil, thymol and carvacrol against sensitive and resistant microbial isolates from dogs with otitis externa. Veterinary Dermatology. Cited by: 106

3. Deo, P., Hewawasam, E., Karakoulakis, A., Claudie, D. J., Nelson, R., & Vemulpad, S. (2016). In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE), and digestive enzymes linked to diabetes. BMC Complementary and Alternative Medicine, 16(1), 435. Cited by: 61

4. Bergamin, A., Mantzioris, E., Cross, G., Deo, P., Garg, S., & Hill, A. M. (2019). Nutraceuticals: Reviewing their role in chronic disease prevention and management. Pharmaceutical Medicine, 33(4), 291–309. Cited by: 60

5. Fenech, M., Knasmueller, S., Knudsen, L. E., Kirsch-Volders, M., Deo, P., … & Bonassi, S. (2021). “Micronuclei and Disease” special issue: Aims, scope, and synthesis of outcomes. Mutation Research/Reviews in Mutation Research, 788, 108384. Cited by: 54

6. Ferro, S., Amorico, T., & Deo, P. (2018). Role of food sanitising treatments in inducing the ‘viable but nonculturable’ state of microorganisms. Food Control, 91, 321–329. Cited by: 54